NASDAQ:CALC CalciMedica Q2 2025 Earnings Results & Report $1.17 -0.05 (-4.10%) Closing price 04:00 PM EasternExtended Trading$1.16 -0.01 (-0.85%) As of 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. CalciMedica met analyst earnings expectations in its Q2 2025 results, released August 12, 2025. The company reported EPS of -$2.00 versus the -$2.00 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 12, 2025TimeBefore Market Opens CalciMedica EPS ResultsActual EPS-$2.00Consensus EPS -$2.00Beat/MissMet ExpectationsOne Year Ago EPSN/AEPS Beat Rate7 of last 8 quartersCalciMedica Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile CalciMedica Q2 2025 Earnings FAQ Did CalciMedica beat earnings estimates for Q2 2025? CalciMedica (NASDAQ:CALC) reported earnings of -$2.00 per share for Q2 2025, matching the consensus estimate of -$2.00. The report was announced on Tuesday, August 12, 2025. CalciMedica Earnings HeadlinesFY2026 EPS Estimates for CalciMedica Raised by HC WainwrightNovember 14, 2026 | americanbankingnews.comCalciMedica, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2026November 11, 2026 | marketscreener.comMWorse than socialismDonald Trump and Bernie Sanders rarely agree on anything, yet both are steering the country toward the same economic system, according to veteran analyst Porter Stansberry. The government has already taken stakes in companies like Intel, Lithium Americas, and MP Materials, while political rhetoric on both sides points toward deeper centralization. Stansberry has spent months investigating what this bipartisan shift could mean for investors navigating the months ahead.November 18 at 1:00 AM | Porter & Company (Ad)CalciMedica Reports Third Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesNovember 10, 2026 | globenewswire.comCalciMedica (CALC) Set to Release Earnings on WednesdayNovember 10, 2026 | americanbankingnews.comCalciMedica to Participate in the Guggenheim 3rd Annual Healthcare Innovation ConferenceNovember 3, 2026 | globenewswire.comSee More CalciMedica Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CalciMedica? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CalciMedica and other key companies, straight to your email. Email Address About CalciMedicaCalciMedica (NASDAQ:CALC) is a clinical-stage biopharmaceutical company developing treatments for serious inflammatory and immunologic conditions. Its research focuses on calcium release-activated calcium (CRAC) channels, which play a role in immune-cell activity and inflammation. The company’s lead drug candidate, Auxora, is an investigational CRAC channel inhibitor being studied for acute inflammatory conditions, including acute pancreatitis. CalciMedica has no marketed products; its candidates remain in clinical development. Based in La Jolla, California, CalciMedica became a publicly traded company in 2024 through a business combination with Orion Acquisition Corp. The company’s work is centered on developing and testing its therapies, rather than commercial product sales.View CalciMedica ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes ShapeGeneral Motors Faces a Cost Squeeze as Factory Automation Takes Center StageNVIDIA's Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?5 Consumer Discretionary Plays Showing Strength During the Tech Sell-OffAMD Bets $8.2B on Physical AI: Could Robotics Be Its Next Growth Frontier?Viking’s Low-Water Miss Looks Like a Buy-the-Dip OpportunityDisney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout Upcoming Earnings NetEase (11/19/2026)Alibaba Group (11/19/2026)PDD (11/19/2026)Ross Stores (11/19/2026)Walmart (11/19/2026)Intuit (11/19/2026)Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.